Precision BioSciences (NASDAQ:DTIL) Posts Earnings Results, Beats Estimates By $0.57 EPS

Precision BioSciences (NASDAQ:DTIL) posted its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.57, reports. The business had revenue of $1.25 million for the quarter, compared to analysts’ expectations of $1.38 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%.

Precision BioSciences Stock Performance

NASDAQ:DTIL opened at $6.97 on Wednesday. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $9.62. The stock has a fifty day simple moving average of $6.83 and a 200-day simple moving average of $6.53.

Wall Street Analyst Weigh In

A number of analysts recently commented on DTIL shares. HC Wainwright reissued a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Wall Street Zen cut shares of Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Precision BioSciences has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.